Upload
nani-karnam-vinayakam
View
153
Download
5
Tags:
Embed Size (px)
DESCRIPTION
It helps for both UG and PG students of medical , pharmacy, Pharm D and ayurveda students
Citation preview
Asthma- A Clinical Review
and its Management
K V GOPINATH M Pharm(PhD)CPhTHospital Pharmacist
Tirumala Tirupati DevasthanamsTirupati -517 501
Magnitude of the problem
>5000 patients die from asthma
1.9 million ER visits (1995)
Self reported asthma in the US was 14.6 million
Estimated patients rose to 17 million (1998)
Overall asthma health expenditure was at $6.2 billion (1990)
Indian Scenario 15- 20 million asthmatics
Asthma prevalence to be 12% in school children
Significant cause of school/work absence
Health care expenditures very high
Morbidity and mortality are on the rise JAPI 2002; Vol 50: 462
The Treatment Gap in Asthma
Patients are not detected
Do not seek medical attention
No access to health service
Missed diagnosis (bronchitis, LRTI)
Definition
“A chronic inflammatory disorder of the airways”
NAEPP.Expert Panel Report 2. Guidelines for the diagnosis and management of asthma: NIII publication, 1997.
Risk Factors that Lead to Asthma Development
Respiratory infections
Allergens
Environment
Emotions
Exercis
Drugs/preservatives
Occupational Stimuli
Pathophysiology
Risk Factor
Inflammation
Airway Hyper responsiveness
Airflow limitation
Risk Factor Symptoms
Current Understanding of Asthma
A chronic inflammatory disorder of the airway
Infiltration of mast cells, eosinophils and lymphocytes
Airway hyperresponsiveness
Recurrent episodes of wheezing, coughing and shortness of breath
Widespread, variable and often reversible airflow limitation
DIAGNOSIS OF ASTHMA
Detailed History of Asthma & Physical examination
X-Ray
Blood & sputum test
Allergy prick skin testing & Challenge tests
Differential diagnosis
A trial use of asthma medications
Pulmonary Function Test
Diagnostic testing
E.g. A patient with 35 yrs;M; Height 149 cm, and Weight 49kgs
Pred: FEV1 =1.555 L Pre =1.231L
Post =1.369 L % Change = 11.21
Peak Flow Meter/Spiro meter
Classification of Asthma Severity
Step 4 Severe persistent
FEV1 or PEF<60% Predicted
Step 3Moderate Persistent
FEV1orPEF>60%<80% Predicted
Step 2Mild
FEV1 or PEF >80% predicted
Step1:Intermittent FEV1 or PEF >80% predicted
Goals to Be Achieved in Asthma Control Achieve and maintain control of symptoms
Prevent asthma episodes
Minimal use of reliever medication
No emergency visits to doctors or hospitals
Maintain normal activity levels and Maintain pulmonary function
Minimal /No adverse effects from medicine
Tool Kit for Achieving Management Goals
Preventers
Peak Flow meter
Patient education
What are Preventers?
Prevent future attacks
Long term control of asthma / regular use only
Prevent airway remodeling
Anti-inflammatory
Takes time to act (1-3 hours)
Long-term effect (12-24 hours)
PREVENTERS
CORTICOSTEROIDS ANTI LEUCOTRIENES Prednisolone, Betamethasone Montelukast, Beclomethasone, Budesonide Zafirlukast, Fluticasone
XANTHINESTheophylline SR
LONG ACTINGS 2 AGONISTS MAST CELL STABILIZERESBambuterol, Salmeterol SodiumcromoglycateFormoterol
COMBINATIONSSalmeterol/Fluticasone Formoterol/Budesonide Salbutamol/Beclomethasone
What Are Relievers?
Rescue medications Quick relief of symptoms Used during acute attacks
Action lasts 4-6 hrs
Not for regular use
Rescue Medication
SALBUTAMOL INHALER
100 mcg: 1 or 2 puffs as necessary
LEVOSALBUTAMOL INHALER
50 mcg : 1 or 2 puffs as necessary
Ideal combination
Formoterol ( fast relief and SR ) + Budesonide
Dose: 1- 4 puffs ( OD/BD )
Another combination
Salmeterol + Fluticasone
All Asthma Drugs Should Ideally Be Taken Through The Inhaled Route
Oral Slow onset of action
Large dosage used
Greater side effects Not useful in acute symptoms
Inhaled route Rapid onset of action
Less amount of drug used
Better tolerated
Treatment of choice
In acute symptoms
Aerosol delivery systems
Metered dose inhalers
Dry powder inhalers (Rota haler)
Spacers / Holding chambers
Rota haler - The dry powder advantage
Overcomes hand-lung coordination problems that are encountered with MDIs
Can be easily used by children, elderly and arthritic
patients
Can take multiple inhalations if the entire drug has not
been inhaled in one
Advantages of Spacer
No co-ordination required
No cold - Freon effect
Reduced oropharyngeal deposition
Increased drug deposition
Age-wise selection of inhaler devices
< 3 years – MDI + Spacer + Mask or nebulisers
3 – 5 years – MDI + Spacer + Mask or Rotahaler
5 – 8 years – Rotahaler or MDI + Spacer
> 8 years – Rotahaler or MDI + Spacer
Patient Education
Patient Education Explain nature of the disease (i.e. inflammation) Explain action of prescribed drugs Stress need for regular, long-term therapy Allay fears and concerns Peak flow reading Treatment diary / booklet
Key Messages
It can happen to anybody It is not caused by supernatural forces Asthma is not contagious It produces recurrent attacks of cough with or without
wheeze Between attacks people with asthma lead normal lives
as anyone else In most cases there is some history of allergy in the
family.
Key Messages
Asthma can be effectively controlled, although it cannot be cured.
Effective asthma management programs include education, objective measures of lung function, environmental control, and pharmacologic therapy
. A stepwise approach to pharmacologic therapy is
recommended. The aim is to accomplish the goals of therapy with the least possible medication.
Objectives
To assess the health related quality of life with respect to the pulmonary function
To assess the knowledge, attitude and practices of asthmatics regarding their diseases, medication and its management.
To evaluate the patient adherence in asthmatics receiving medications.
To appropriately counsel patients on the proper use of medications for asthma and methods for prevention.
To evaluate the outcome of patient counseling.
Materials and Methods
Spirometer
Health related quality of life
Demographic data
Knowledge, attitude and practice
Compliance assessment
Statistical analysis
66.66
%
33.33
%
37.50
%
62.50
%
47.22
%
52.77
%
Male Female
Sex
% of
Patie
nts
Pharmaceutical care group n=12 Usual care group n=24 Total study population n=36
Demographic data based on sex
Demographic data based on age
16.6
6%
83.3
3%
0%
12.5
0%
75%
12.5
0%
13.8
8%
77.7
7%
33%
12 to 18 19 to 60 > 60
Age in Years
% o
f P
atie
nts
Pharmaceutical care group n=12 Usual care group n=24 Total study population n=36
Demographic data based on education
16.6
6%
25%
16.6
6%
8.33
%
33.3
3%
12.5
0% 16.6
6%
25%
25%
20.8
3%
13.8
8%
19.4
4%
22.2
2%
19.4
4% 25%
Illiterate Middle School High/higher Secondary College
Education
% o
f pat
ient
s
Pharmaceutical care group n=12 Usual care group n=24 Total study population n=36
Demographic data based on occupation
25%
33.3
3%
8.33
%
25%
8.33
%
20.8
3%
37.5
0%
16.6
6% 20.8
3%
4.16
%
22.2
2%
36.1
1%
13.8
8%
22.2
2%
5.55
%
Student House w ife Business Employee Labour
Occupation
% o
f P
atie
nts
Pharmaceutical care group n=12 Usual care group n=24 Total study population n=36
Demographic data based on social habits (Alcohol)
8.33
%
91.6
6%
12.5
0%
87.5
0%
11.1
1%
88.8
8%
Yes No
Alcohol - Status
% o
f P
atie
nts
Pharmaceutical care group n = 12 Usual care group n = 24 Total study population + 36
Demographic data based on social habits (Smoking)
8.33
%
91.6
6%
25%
75%
19.4
4%
80.5
5%
Yes No
Smoking status
% o
f P
atie
nts
Pharmaceutical care group n = 12 Usual care group n = 24 Total study population + 36
Demographic data based on treatment profile
16.6
6%
66.6
6%
16.6
6%25%
58.3
3%
0
22.2
2%
61.1
1%
25%
<3 3 to 5 >5
No. of drugs used
% o
f Pat
ient
s
Pharmaceutical care group n = 12 Usual care group n = 24 Total study population + 36
Drug Usage in Study Population
91.6
6%
41.6
6%
16.6
6%
0% 0%
33.3
3%
33.3
3%
8.33
%
33.3
3%
66.6
6%
16.6
6%
16.6
6%
0%
25%
25%
0%
8.33
%
79.1
6%
45.8
3%
20.8
3%
4.16
%
8.33
% 16.6
6%
4.16
%
4.16
%
25%
75%
0%
29.1
6%
8.33
%
12.5
0%
12.5
0%
8.33
%
4.16
%
Name of the drugs
% o
f Pat
ient
s
Pharmaceutical Care Group Usual care group
DIAGNOSIS OF ASTHMA: % REVERSIBILITY
Parameter Pharmaceutical Care
Group (%)
Usual Care Group (%)
Reversibility 23.01±16.73 15.03±12.14
Phauc Nguyen.Counseling Patients on Management of Asthma. J of Asthma.2001: 9-18.
Comparative Statement Of PFT Parameters, Percentage Predicted
Group PFT parameter
Base Line
Follow Up 1
Follow Up 3
Follow Up 6
Pharm. CareGroup
C 1.48 1.96 (32%)
2.31 (56%)
2.48 (67.56%)
FVC 2.01 2.40 (19%)
2.75 (37%)
2.87 (43%)
FEV1/FVC% 73.7 82 (11.3%)
85 (15.3%)
86 (17%)
PEF 254 357 (40.6%)
380 (49.7%)
396 (56%)
Usual careGroup
FEV1 1.63 1.65 (1.22%)
1.71 (8%)
1.78 (9.20%)
FVC 2.08 2.1 (0.23%) 2.1 (0.23)
2.12 (2%)
FEV1/FVC% 78.4 80 (2.1%)
83.5 (6.5%)
84.5 (7.7%)
PEF 302 279 (-7.8%)
290 (-3.99%)
303 (0.33%)
Mean Medication Knowledge Assessment score
Characteristic population
Base line Follow up-6 % Change p value
Pharma. care group
24.41+9.64 54.33+4.79 122.57 *p=<0.0001
Usual care group
14.30+8.18 20.87+16.00 45.94 p=<0.0868
Patient Compliance: Pill Count Method
The percentage of compliance was more in intervention 90.55
Health Related Quality Of Life
Characteristic population
Component
0-45th day 46th - 90th day
% *Change
P value
Pharmaceutical Care Group
Symptoms 45.40+22.96 9.644+7.90 -78.76 *P= <0.0001
Activity 46.74+28.69 4.14+8.51 -91.14 *P= <0.0001
Impact 37.02+16.08 4.33+8.03 -88.30 *P= <0.0001
Total score
41.31+18.50 5.19+7.30 -87.43 *P=<0.0001
Usual care Group
Symptoms 8.82+20.79 13.44+2.71 52.38 P=0.3792
Activity 21.79+23.60 12.63+17.02 -0.42 P=0.1472
Impact 18.68+18.72 15.76+13.85 -15.63 P=0.5598
Total score
17.89+18.71 14.42+12.15 -19.39 P=0.4689
-78.76
52.38
-100
-80
-60
-40
-20
0
20
40
60
Studypopulation
% o
f Sym
pto
m S
core
PharmaceuticalCare GroupUsual CareGroup
Percentage Improvement of SGRQ Symptom Scores
-91.14
-0.42
-100
-80
-60
-40
-20
0
Study population
% o
f SG
RQ
Act
ivity
sco
re
Pharmaceutical CareGroupUsual Care Group
Percentage Improvement of SGRQ Activity Scores
-88.3
-0.42
-100-90-80-70-60-50-40-30-20-10
0
Study population
% o
f SG
RQ
Imp
act
sco
rePharmaceuticalCare Group
Usual CareGroup
Percentage Improvement of SGRQ Impact Scores
-87.43
-19.39
-100
-90
-80
-70
-60
-50
-40
-30
-20
-10
0
Study population
% o
f S
GR
Q t
ota
l score
PharmaceuticalCare GroupUsual CareGroup
Percentage Improvement of SGRQ Total Scores
Conclusion
• The pharmaceutical intervention would improve the pulmonary function and HRQOL appears to hi-light different aspects of disease severity in asthma.
Future Action Plan
To assess the safe, appropriate, and cost effective management of asthma.
To compare the efficiency of bronchodilators used in practice.
Wheezing Disturbed sleep
Breathlessness Cough and Cold
How to use Rota haler
oral metered-dose inhalers
How to use Spacer